TCRX
TScan Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 4 ▲ TScan Therapeutics reported financial results for Q4 and full-year 2…
- Jun 22 FDA: TScan Therapeutics Announces Positive Initial Data from Co…
- Jun 22 ▲ TScan Therapeutics reported positive initial data from Cohort C of t…
- Jun 22 ▲ TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-…
- Aug 12 ▼ TScan Therapeutics reported Q2 2026 results with revenue of $1.1M (d…
- Aug 12 ▼ TScan Therapeutics reported Q2 2026 EPS of -$0.23, a 15% miss vs con…
- Aug 18 ▼ TScan Therapeutics disclosed that Amgen terminated their Research Co…
- Sep 2 ▼ TScan Therapeutics announced a drastic strategic reorganization: a 7…
- Sep 8 ▼ HC Wainwright & Co. downgrades
- Sep 15 ▼ Short interest jumps 30.3% to 2.28M
- Oct 26 ▼ TScan Therapeutics is holding a special meeting on November 20, 2026…
- Nov 12 ▼ The company paused enrollment in its Phase 3 ALLOHA-2 study of TSC-1…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q3 2026: 2 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
7 of 11 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −11.3% to 2.02M shares. 4.7 days to cover, ≈3.2% of shares.
- TrendDOWNTREND
43% below its 50-day average. New closing low $0.1450 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | TRIM | $188.0K |
| MARSHALL WACE, LLP | TRIM | $83.6K |
| UBS Group AG | ADD | $34.1K |
| MORGAN STANLEY | TRIM | $32.9K |
| JANE STREET GROUP, LLC | TRIM | $28.4K |
| HRT FINANCIAL LP | TRIM | $19.0K |
| FMR LLC | ADD | $629.00 |
| JPMORGAN CHASE & CO | NEAR_EXIT | $545.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is below the lowest target. Median implies +590%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Sep 3, 2026 | Wedbush DOWNGRADE | Neutral |
| Sep 2, 2026 | Needham DOWNGRADE | Hold |
| Aug 12, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jun 23, 2026 | Wedbush REITERATE | Outperform |
| Jun 23, 2026 | Needham REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
MacBeath Gavin Chief Executive Officer Oct 1, 2026 | AWARD | 1,000,000 sh |
ZDRAVESKI ZORAN See Remarks Oct 1, 2026 | AWARD | 300,000 sh |
Gruia Gabriela Director May 20, 2026 | AWARD | 67,000 sh |
Dorton Katina Director May 20, 2026 | AWARD | 67,000 sh |
Klencke Barbara Director May 20, 2026 | AWARD | 67,000 sh |
Woods Keith Director May 20, 2026 | AWARD | 67,000 sh |
Nicholson Garry A Director May 20, 2026 | AWARD | 67,000 sh |
BAKER BROS. ADVISORS LP Director May 20, 2026 | AWARD | 67,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$0.83 | -$0.88–-$0.78 | -6.8% | $2.6M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 2 press releases · 1 bullish · 6 bearish · 6 neutral- BEARISH 8-KNov 12, 2026
The company paused enrollment in its Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital…
The Phase 3 ALLOHA-2 pause and pivot to preclinical in vivo programs push any potential revenue-generating milestones years out, while cash runway only extends to Q4 2027. Monitor for partnership…
- BEARISH DEF 14AOct 26, 2026
TScan Therapeutics is holding a special meeting on November 20, 2026, to seek stockholder approval…
Monitor the November 20 special meeting vote outcome and the board's subsequent decision on the split ratio. If approved, watch for the actual ratio selected and whether the split successfully lifts…
- NEUTRAL 8-KOct 16, 2026
Two board members, Garry Nicholson and Gabriela Gruia, M.D., resigned from TScan Therapeutics'…
Routine board committee reshuffle with no operational or financial implications. No immediate trading catalyst.
- NEUTRAL 8-KSep 30, 2026
TScan Therapeutics formalized separation agreements with former CFO Jason Amello and former CMO…
This filing formalizes previously announced C-suite departures with no new financial surprises. Monitor the Q3 2026 10-Q for the full separation agreement exhibits and any updates on the strategic…
All TCRX filing & press-release reports (15)
- 8-K reportNov 12, 2026
- DEF 14A reportOct 26, 2026
- 8-K reportOct 16, 2026
- 8-K reportSep 30, 2026
- SC 13G reportSep 25, 2026
- 8-K reportSep 11, 2026
- 8-K reportSep 2, 2026
- 8-K reportAug 18, 2026
- 8-K reportAug 12, 2026
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportJun 22, 2026
- PRESS-RELEASE reportJun 22, 2026
- 8-K reportMay 6, 2026
- 8-K reportApr 2, 2026
- PRESS-RELEASE reportMar 4, 2026